<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB</h1>

    <table>
      <tr><th>Ticker</th><td>INMB</td></tr>
      <tr><th>Float</th><td>22.1 M</td></tr>
      <tr><th>IO</th><td>17.54%</td></tr>
      <tr><th>MC</th><td>34.7 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>INmune Bio (NASDAQ: INMB) announced a webinar on February 26, 2026 at 1:00 p.m. ET to present new clinical data from the MissionEB Phase III trial of CORDStrom™ for recessive dystrophic epidermolysis bullosa (RDEB). The webinar will focus on systemic, disease‑modifying effects versus topical care, highlighting EBDASI skin score changes, pediatric weight gain, reductions in pain and itch, and improved quality of life. Presenters include Dr. Anna Martinez (principal investigator of MissionEB) and Prof. Mark Lowdell (CSO and co-founder of INmune). Registration details and a link are provided in the release. The release reiterates forward‑looking risk disclosures that CORDStrom and other platforms are investigational and not approved by regulatory authorities.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Company to present Phase III MissionEB clinical data for CORDStrom, signaling progress in development.</li><li>Release highlights several clinically relevant endpoints: EBDASI skin score improvements, pediatric weight gain, symptom reductions (pain and itch), and quality of life gains.</li><li>Webinar features principal investigators and senior scientific leadership, providing investigator-level insights.</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Press release does not include detailed trial data or quantitative results; data will be presented at the webinar.</li><li>CORDStrom and other INmune product candidates are investigational and not approved by the FDA or other regulators.</li><li>Forward-looking statements note risks including potential inability to achieve expected results, produce drug supply, or obtain regulatory approval.</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/7c1e06d6-f277-49f1-9f41-9598fb4de114" target="_blank">Original Article</a>
    </div>

    <div class="small">INMB • TradersLink AI News</div>
  </div>
</body>
</html>